📊 CRNX Key Takeaways
Is Crinetics Pharmaceuticals, Inc. (CRNX) a Good Investment?
Crinetics shows impressive revenue growth (641% YoY) from early commercialization, but operating losses of $140.4M against $10.7M in revenue are unsustainable. With $114.3M cash and $124.7M quarterly burn rate, runway is less than 12 months without significant revenue acceleration or cost restructuring. Strong balance sheet provides temporary cushion, but trajectory without material improvement leads to dilutive capital raise or failure.
Crinetics shows exceptional balance-sheet strength with nearly $1.0B of equity, very high liquidity, and no meaningful leverage, which gives it time to fund development. However, the core fundamentals remain weak: revenue is still immaterial relative to the cost base, losses are extremely large, and cash burn is severe, indicating that current growth has not translated into a durable operating model.
Crinetics Pharmaceuticals, Inc. Key Strengths (CRNX)
- Exceptional revenue growth trajectory (+640.7% YoY) indicates successful product commercialization
- Strong balance sheet with $1.3B stockholders' equity and minimal debt (0.00x leverage)
- Excellent liquidity position with 18.6x current ratio and $114.3M cash reserves
- Low capital intensity ($820K capex) typical of pharmaceutical distribution business
- Very strong liquidity profile with current and quick ratios above 12x
- Debt-free capital structure reduces financial risk and interest burden
- Revenue grew sharply year over year, indicating some commercial or collaboration momentum
CRNX Stock Risks: Crinetics Pharmaceuticals, Inc. Investment Risks
- Unsustainable cash burn ($124.7M operating outflow) against minimal revenue base ($10.7M), implying <12 month cash runway
- Massive operating losses (-$140.4M) with -1307.8% operating margin indicate pre-profitability at scale impossible at current metrics
- Equity dilution risk imminent absent dramatic revenue acceleration or major cost restructuring; likely requires capital raise within 9-12 months
- Pharma-specific execution risks: patient adoption volatility, pricing pressure, regulatory changes, competitive dynamics in treatment category
- Operating and net margins are deeply negative, showing no near-term profitability
- Free cash flow burn is very high, which can erode the cash cushion if not improved
- Revenue quality appears weak because the revenue base is too small to support the current expense structure
Key Metrics to Watch
- Quarterly revenue run rate and growth sustainability (declining growth would accelerate cash crisis)
- Operating cash burn trend and path to cash flow breakeven (must improve 10-15x to reach viability)
- Cash balance depletion rate and months of runway remaining (critical inflection point <6 months)
- Gross margin progression and operating expense reduction initiatives (required for profitability)
- Quarterly operating cash burn and free cash flow trend
- Revenue scale-up relative to R&D and SG&A growth
Crinetics Pharmaceuticals, Inc. (CRNX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 18.60x current ratio provides a solid financial cushion.
CRNX Profit Margin, ROE & Profitability Analysis
CRNX vs Healthcare Sector: How Crinetics Pharmaceuticals, Inc. Compares
How Crinetics Pharmaceuticals, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Crinetics Pharmaceuticals, Inc. Stock Overvalued? CRNX Valuation Analysis 2026
Based on fundamental analysis, Crinetics Pharmaceuticals, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Crinetics Pharmaceuticals, Inc. Balance Sheet: CRNX Debt, Cash & Liquidity
CRNX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Crinetics Pharmaceuticals, Inc.'s revenue has grown significantly by 217% over the 5-year period, indicating strong business expansion. The most recent EPS of $-3.69 indicates the company is currently unprofitable.
CRNX Revenue Growth, EPS Growth & YoY Performance
CRNX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $361.0K | -$96.8M | $-1.04 |
| Q3 2025 | N/A | -$76.8M | $-0.96 |
| Q2 2025 | $399.0K | -$74.1M | $-0.94 |
| Q1 2025 | $361.0K | -$66.9M | $-0.93 |
| Q3 2024 | N/A | -$57.5M | $-0.96 |
| Q2 2024 | $399.0K | -$51.0M | $-0.94 |
| Q1 2024 | $640.0K | -$46.0M | $-0.85 |
| Q3 2023 | $346.0K | -$41.9M | $-0.78 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Crinetics Pharmaceuticals, Inc. Dividends, Buybacks & Capital Allocation
CRNX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Crinetics Pharmaceuticals, Inc. (CIK: 0001658247)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CRNX
What is the AI rating for CRNX?
Crinetics Pharmaceuticals, Inc. (CRNX) has a Combined AI Grade of C from Claude (C) and ChatGPT (C) with 77% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CRNX's key strengths?
Claude: Exceptional revenue growth trajectory (+640.7% YoY) indicates successful product commercialization. Strong balance sheet with $1.3B stockholders' equity and minimal debt (0.00x leverage). ChatGPT: Very strong liquidity profile with current and quick ratios above 12x. Debt-free capital structure reduces financial risk and interest burden.
What are the risks of investing in CRNX?
Claude: Unsustainable cash burn ($124.7M operating outflow) against minimal revenue base ($10.7M), implying <12 month cash runway. Massive operating losses (-$140.4M) with -1307.8% operating margin indicate pre-profitability at scale impossible at current metrics. ChatGPT: Operating and net margins are deeply negative, showing no near-term profitability. Free cash flow burn is very high, which can erode the cash cushion if not improved.
What is CRNX's revenue and growth?
Crinetics Pharmaceuticals, Inc. reported revenue of $10.7M.
Does CRNX pay dividends?
Crinetics Pharmaceuticals, Inc. does not currently pay dividends.
Where can I find CRNX SEC filings?
Official SEC filings for Crinetics Pharmaceuticals, Inc. (CIK: 0001658247) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CRNX's EPS?
Crinetics Pharmaceuticals, Inc. has a diluted EPS of $-1.23.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is CRNX's fundamental grade?
Based on our AI fundamental analysis in June 2026, Crinetics Pharmaceuticals, Inc. has a C grade with 77% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is CRNX stock overvalued or undervalued?
Valuation metrics for CRNX: ROE of -10.0% (sector avg: 15%), net margin of -1,191.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is CRNX's AI grade for 2026?
Our dual AI analysis gives Crinetics Pharmaceuticals, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CRNX's free cash flow?
Crinetics Pharmaceuticals, Inc.'s operating cash flow is $-124.7M, with capital expenditures of $820.0K. FCF margin is -1,169.4%.
How does CRNX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1,191.0% (avg: 12%), ROE -10.0% (avg: 15%), current ratio 18.60 (avg: 2).